DVDarryl C. De Vivo

Darryl C. De Vivo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Darryl C. De Vivo has a total of 252 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A therapeutic role for a regulatory GLUT1–associated lncRNA in GLUT1-deficient mice

    by Maoxue Tang, Sasa Teng, Yueqing Peng, Ashley Y. Kim, Yoon-Ra Her, Peter Canoll, Jeffrey N. Bruce, Phyllis L. Faust, Kailash Adhikari, Darryl C. De Vivo, et al.

    The mammalian brain relies primarily on glucose for its energy needs. Delivery of this nutrient to the brain is mediated by the glucose transporter-1 (GLUT1) protein. Low GLUT1 thwarts glucose entry into the brain, causing an energy crisis and triggering, in one instance, the debilitating neurodevelopmental condition known as GLUT1 deficiency syndrome (GLUT1DS). Current treatments for GLUT1DS are suboptimal, as none address the root cause — low GLUT1 — of the condition. Levels of this transporter must respond rapidly to the brain’s changing energy requirements. This necessitates fine tuning its expression. Here, we describe a long-noncoding RNA (lncRNA) antisense to GLUT1 (SLC2A1) and show that it is involved in such regulation. Raising levels of the lncRNA had a concordant effect on GLUT1 in cultured human cells and transgenic mice; reducing levels elicited the opposite effect. Delivering the lncRNA to GLUT1DS model mice via viral vectors induced GLUT1 expression, enhancing brain glucose levels to mitigate disease. Direct delivery of such a lncRNA to combat disease has not been reported previously and constitutes, to our knowledge, a unique therapeutic paradigm. Moreover, considering the importance of maintaining homeostatic GLUT1 levels, calibrating transporter expression via the lncRNA could become broadly relevant to myriad conditions, including Alzheimer’s disease, wherein GLUT1 is perturbed.

  • Open Access

    Beyond Contractures in Spinal Muscular Atrophy: Identifying Lower-Limb Joint Hypermobility

    by Elizabeth R. Harding, Cara H. Kanner, Amy Pasternak, Allan M. Glanzman, Sally Dunaway Young, Ashwini K. Rao, Michael P. McDermott, Zarazuela Zolkipli-Cunningham, John W. Day, Richard S. Finkel, et al.

    Background: The natural history of spinal muscular atrophy (SMA) is well understood, with progressive muscle weakness resulting in declines in function. The development of contractures is common and negatively impacts function. Clinically, joint hypermobility (JH) is observed but is poorly described, and its relationship with function is unknown. Methods: Lower-limb ROM (range of motion) assessments of extension and flexion at the hip, knee, and ankle were performed. ROMs exceeding the published norms were included in the analysis. The functional assessments performed included the six-minute walk test (6 MWT) and the Hammersmith Functional Motor Scale—Expanded (HFMSE). Results: Of the 143 participants, 86% (n = 123) had at least one ROM measure that was hypermobile, and 22% (n = 32) had three or more. The HFMSE scores were inversely correlated with hip extension JH (r = −0.60, p = 0.21; n = 6) and positively correlated with knee flexion JH (r = 0.24, p = 0.02, n = 89). There was a moderate, inverse relationship between the 6 MWT distance and ankle plantar flexion JH (r = −0.73, p = 0.002; n = 15). Conclusions: JH was identified in nearly all participants in at least one joint in this study. Hip extension, knee flexion and ankle plantar flexion JH was associated with function. A further understanding of the trajectory of lower-limb joint ROM is needed to improve future rehabilitation strategies.


  • Open Access

    Low Bone Mass in Ambulatory Spinal Muscular Atrophy: A Proactive Approach for an Often-Overlooked Impairment

    by Caitlin Trancho, Bailey Stickney, Stacy Kinirons, David Uher, Cara H. Kanner, Ashwini K. Rao, Michael P. McDermott, Carol Ewing Garber, Darryl C. De Vivo, Jacqueline Montes

    Background: Individuals with spinal muscular atrophy (SMA) are at risk for low bone mass (LBM). The objectives of this study were to compare bone mineral density (BMD) in ambulatory SMA and control participants, identify LBM, and evaluate the associations of function and physical activity (PA) with LBM. Methods: Thirty-five children and adults, nineteen SMA and sixteen healthy controls, participated. Dual-energy absorptiometry determined BMD, T-scores, and Z-scores. The six-minute walk test (6MWT) and Timed Up and Go (TUG) assessed function. The International Physical Activity Questionnaire Short Form (IPAQ-SF) evaluated PA. Results: Group comparisons and factors associated with BMD were analyzed. Area under the receiver operating characteristic (ROC) curve (AUC) assessed the ability to identify individuals with LBM. SMA participants had lower BMD (p < 0.001) and increased odds of having LBM relative to controls (OR = 16.7; 95%CI: 1.8–152.8; p = 0.004). Conclusions: Ten SMA and one control had LBM. Z-score was associated with 6MWT (rs = 0.65; p < 0.001) and TUG (rs = −0.61; p < 0.001). IPAQ-SF and Z-score were weakly associated (rs = 0.36, p < 0.03). 6MWT (AUC: 0.80; 95% CI: 0.65–0.94; p = 0.006) and TUG (AUC: 0.85; 95% CI: 0.71–0.98; p = 0.002) identified individuals with LBM. Function, assessed by the 6MWT and TUG, is associated with BMD and shows promise for use in identifying individuals with LBM.


  • Open Access

    Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function

    by Sally Dunaway Young, Jacqueline Montes, Allan M. Glanzman, Richard Gee, John W. Day, Richard S. Finkel, Basil T. Darras, Darryl C. De Vivo, Giulia Gambino, Richard Foster, et al.

    Nusinersen has been shown to improve or stabilize motor function in individuals with spinal muscular atrophy (SMA). We evaluated baseline scoliosis severity and motor function in nusinersen-treated non-ambulatory children with later-onset SMA. Post hoc analyses were conducted on 95 children initiating nusinersen treatment in the CHERISH study or SHINE long-term extension trial. Participants were categorized by baseline Cobb angle (first nusinersen dose): ≤10°, >10° to ≤20°, and >20° to p = 0.02) and a −1.2 (95% CI −2.1, −0.4) point decrease in RULM (p = 0.006) at Day 930. Treatment with nusinersen was associated with improvements/stabilization in motor function in all groups, with greater response in those with no/mild scoliosis at baseline.


  • Top Cited Papers
    Open Access

    Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of theNURTUREstudy

    by Thomas O. Crawford, Kathryn J. Swoboda, Darryl C. De Vivo, Enrico Bertini, Wuh‐Liang Hwu, Richard S. Finkel, Janbernd Kirschner, Nancy L. Kuntz, Aledie Navas Nazario, Julie A. Parsons, et al.

    Introduction/Aims: NURTURE (NCT02386553) is an open‐label study of nusinersen in children (twoSMN2copies,n = 15; threeSMN2copies,n = 10) who initiated treatment in the presymptomatic stage of spinal muscular atrophy (SMA). A prior analysis after ~3 y showed benefits on survival, respiratory outcomes, motor milestone achievement, and a favorable safety profile. An additional 2 y of follow‐up (data cut: February 15, 2021) are reported.Methods: The primary endpoint is time to death or respiratory intervention (≥6 h/day continuously for ≥7 days or tracheostomy). Secondary outcomes include overall survival, motor function, and safety.Results: Median age of children was 4.9 (3.8–5.5) y at last visit. No children have discontinued the study or treatment. All were alive. No additional children utilized respiratory intervention (defined per primary endpoint) since the prior data cut. Children with threeSMN2copies achieved all World Health Organization (WHO) motor milestones, with all but one milestone in one child within normal developmental timeframes. All 15 children with twoSMN2copies achieved sitting without support, 14/15 walking with assistance, and 13/15 walking alone. Mean Hammersmith Functional Motor Scale Expanded total scores showed continued improvement. Subgroups with twoSMN2copies, minimum baseline compound muscle action potential amplitude ≥2 mV, and no baseline areflexia had better motor and nonmotor outcomes versus all children with twoSMN2copies.Discussion: These results demonstrate the value of early treatment, durability of treatment effect, and favorable safety profile after ~5 y of nusinersen treatment. Inclusion/exclusion criteria and baseline characteristics should be considered when interpreting presymptomatic SMA trial data.


  • Open Access

    Measuring Fatigue and Fatigability in Spinal Muscular Atrophy (SMA): Challenges and Opportunities

    by Rafael S. Rodriguez-Torres, David Uher, Emma L. Gay, Giorgia Coratti, Sally Dunaway Young, Annemarie Rohwer, Robert Muni Lofra, Darryl C. De Vivo, Michio Hirano, Nancy W. Glynn, et al.

    Fatigue, a common symptom, together with the characteristic of performance fatigability, are well-documented features of SMA that impact quality of life and function. Importantly, establishing associations between multidimensional self-reported fatigue scales and patient performance has proven difficult. This review was conducted to evaluate the various patient-reported fatigue scales applied in SMA, with the objective of considering the limitations and advantages of each measure. Variable use of fatigue-related nomenclature, including conflicting terminology interpretation, has affected assessment of physical fatigue attributes, specifically perceived fatigability. This review encourages the development of original patient-reported scales to enable perceived fatigability assessment, providing a potential complementary method of evaluating treatment response.


  • Treatments and Outcomes for Patients with Spinal Muscular Atrophy Type 2: Findings from RESTORE Registry (P7-9.010)

    by Laurent Servais, Kamal Benguerba, Darryl C. De Vivo, Jan Kirschner, Francesco Muntoni, Crystal Proud, Eduardo Tizzano, Susana Quijano-Roy, Isabelle Desguerre, Kyoko Saito, et al.

    Objective: We sought to describe real-world treatment patterns and outcomes for patients with SMA type 2 (SMA2) receiving onasemnogene abeparvovec (OA) monotherapy or who switched to OA from nusinersen. Background: Real-world data describing treatment patterns and outcomes for patients with SMA2 are limited. Patients with untreated SMA2 typically have clinically identifiable disease symptoms between 6–18 months of age, and are able to sit independently, but are unable to walk without support. Design/Methods: RESTORE is an ongoing SMA patient registry that captures patient data from a variety of sources. We analyzed changes in motor milestones and motor function scores and assessed treatment-emergent adverse events (TEAEs) for patients who received OA monotherapy or switched to OA from nusinersen. Results: As of Nov. 23, 2021, 34 patients with SMA2 were identified. Six (17.7%), 27 (79.4%), and 1 (2.9%) had two, three, or four SMN2 gene copies, respectively. Median age at SMA diagnosis was 13.0 months. Age at first DMT administration was 14.0 months. Median interval between diagnosis and first DMT was 1 month. Two-thirds (n=23/34) of patients received OA monotherapy; 11 patients switched to OA from nusinersen. Of 23 patients with ≥2 motor milestone assessments (≥1 post-DMT administration), all but three (OA only [n=3]) maintained or achieved new milestones: 14 (60.9%) received OA monotherapy and six (26.1%) switched to OA from nusinersen. Ten of 11 (90.9%) patients evaluable for CHOP INTEND improved/maintained score, with eight (72.7%) achieving a ≥4-point increase. Any-stage TEAEs were recorded for 11/23 (47.8%) patients who received OA monotherapy and 7/11 (63.6%) who switched to OA from nusinersen. AEs in RESTORE are consistent with overall OA experience. No new safety signals were identified. Conclusions: Real-world data from RESTORE indicate that OA is effective and has an acceptable safety profile for patients with SMA2, regardless of prior treatment with nusinersen. Disclosure: The institution of Laurent Servais has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Laurent Servais has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. The institution of Laurent Servais has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avexis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynacure. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Audentes. The institution of Laurent Servais has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Santhera. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RegenexBio. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Anagenesis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catabasis. The institution of Laurent Servais has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evox. Laurent Servais has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lupin. Laurent Servais has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fibrogen. Kamal Benguerba has received personal compensation for serving as an employee of Novartis Gene Therapies. Kamal Benguerba has stock in Novartis Gene Therapies. Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen and Novartis. Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aspa Therapeutics. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genethon. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Jan Kirschner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. The institution of Jan Kirschner has received research support from Biogen. The institution of Jan Kirschner has received research support from Novartis. The institution of Jan Kirschner has received research support from Roche. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sarepta. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Avexis. Dr. Muntoni has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Muntoni has received research support from European Commission. The institution of Dr. Muntoni has received research support from Medical Research Council. The institution of Dr. Muntoni has received research support from Biogen. The institution of Dr. Muntoni has received research support from Muscular Dystrophy UK. The institution of Dr. Muntoni has received research support from MDA USA. The institution of Dr. Muntoni has received research support from Sarepta. The institution of Dr. Muntoni has received research support from Association Francoise Myopathies. Dr. Muntoni has received personal compensation in the range of $0-$499 for serving as a Clinical expert with UK NICE Committee. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avexis. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sarepta. Dr. Proud has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Avexis. Dr. Proud has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Proud has received research support from Biogen. The institution of Dr. Proud has received research support from Sarepta. The institution of Dr. Proud has received research support from Avexis. The institution of Dr. Proud has received research support from PTC. The institution of Dr. Proud has received research support from CSL Behring. The institution of Dr. Proud has received research support from Scholar Rock. The institution of Dr. Proud has received research support from Catabasis. Eduardo Tizzano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Eduardo Tizzano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avexis Novartis. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis GT. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SAnofi Genzyme. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AVEXIS. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS GT. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Prof. Quijano-Roy has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis GT. Prof. Quijano-Roy has received publishing royalties from a publication relating to health care. Prof. Desguerre has nothing to disclose. Kyoko Saito has nothing to disclose. Dr. Raju has nothing to disclose. Ms. LaMarca has received personal compensation for serving as an employee of Novartis Gene Therapies. Dr. Sun has nothing to disclose. Dr. Anderson has nothing to disclose. Mr. Faulkner has received personal compensation for serving as an employee of Novartis Gene Therapies. Dr. Finkel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AveXis. Dr. Finkel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catabasis. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Capricor. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReveraGen. Dr. Finkel has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. Dr. Finkel has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Finkel has received research support from AveXis. The institution of Dr. Finkel has received research support from Biogen. The institution of Dr. Finkel has received research support from Capricor. The institution of Dr. Finkel has received research support from Catabasis. The institution of Dr. Finkel has received research support from ReveraGen. The institution of Dr. Finkel has received research support from Roche. The institution of Dr. Finkel has received research support from Scholar Rock. Dr. Finkel has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Finkel has received intellectual property interests from a discovery or technology relating to health care. Dr. Finkel has received personal compensation in the range of $0-$499 for serving as a Speaker in workshop with National Academy of Sciences. Dr. Finkel has a non-compensated relationship as a advisor with n-Lorem Foundation that is relevant to AAN interests or activities. Dr. Finkel has a non-compensated relationship as a Board Member with EveryLife Foundation that is relevant to AAN interests or activities.

  • Open Access

    2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants

    by Georgia Stimpson, Danielle Ramsey, Amy Wolfe, Anna Mayhew, Mariacristina Scoto, Giovanni Baranello, Robert Muni Lofra, Marion Main, Evelin Milev, Giorgia Coratti, et al.

    The Revised Hammersmith Scale (RHS) is a 36-item ordinal scale developed using clinical expertise and sound psychometrics to investigate motor function in participants with Spinal Muscular Atrophy (SMA). In this study, we investigate median change in the RHS score up to two years in paediatric SMA 2 and 3 participants and contextualise it to the Hammersmith Functional Motor Scale–Expanded (HFMSE). These change scores were considered by SMA type, motor function, and baseline RHS score. We consider a new transitional group, spanning crawlers, standers, and walkers-with-assistance, and analyse that alongside non-sitters, sitters, and walkers. The transitional group exhibit the most definitive change score trend, with an average 1-year decline of 3 points. In the weakest patients, we are most able to detect positive change in the RHS in the under-5 age group, whereas in the stronger patients, we are most able to detect decline in the RHS in the 8–13 age group. The RHS has a reduced floor effect compared to the HFMSE, although we show that the RHS should be used in conjunction with the RULM for participants scoring less than 20 points on the RHS. The timed items in the RHS have high between-participant variability, so participants with the same RHS total can be differentiated by their timed test items.


  • Open Access

    2-year Change in Revised Hammersmith Scale scores in a large cohort of untreated paediatric type 2 and 3 SMA participants

    by Georgia Stimpson, Danielle Ramsey, Amy Wolfe, Anna Mayhew, Mariacristina Scoto, Giovanni Baranello, Robert Muni Lofra, Marion Main, Evelin Milev, Giorgia Coratti, et al.

    The Revised Hammersmith Scale (RHS) is a 36-item ordinal scale developed using clinical expertise and sound psychometrics to investigate motor function in participants with Spinal Muscular Atrophy (SMA). In this study, we investigate median change in the RHS score up to two years in paediatric SMA 2 and 3 participants and contextualise it to the Hammersmith Functional Motor Scale–Expanded (HFMSE). These change scores were considered by SMA type, motor function and baseline RHS score. We consider a new tran-sitional group, spanning crawlers, standers and walkers-with-assistance, and analyse that alongside non-sitters, sitters and walkers. The transitional group exhibit the most de-finitive change score trend, with an average 1-year decline of 3 points. The RHS has a re-duced floor effect compared to the HFMSE, although we show that the RHS should be used in conjunction with the RULM for participants scoring less than 20 points on the RHS. In the stronger participants (between 10 and 42 on the RHS) in the 5-7 age group, both the RHS and HFMSE can detect 1-year change. The timed items in the RHS have high between-participant variability, so participants with the same RHS total can be differentiated by their timed test items.


  • Open Access

    Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States

    by Basil T. Darras, Sabrina Guye, Janine Hoffart, Sophie Schneider, Isaac Gravestock, Ksenija Gorni, Sabine Fuerst‐Recktenwald, Renata S. Scalco, Richard S. Finkel, Darryl C. De Vivo

    Introduction/Aims Data regarding weight, height/length, and growth status of patients with spinal muscular atrophy (SMA) who have received only supportive care are limited. This cross-sectional study describes these measurements in patients with Type 1 and Types 2/3 SMA and compares them with reference values from typically developing children. Methods Retrospective baseline data from three sites in the Pediatric Neuromuscular Clinical Research Network (Boston, New York, Philadelphia) were used. Descriptive statistics for weight, height/length, body mass index-for-age, as well as weight-for-length and absolute and relative deviations from reference values (ie, 50th percentile from World Health Organization/Centers for Disease Control growth charts) were calculated. Furthermore, growth status was reported. Results A total of 91 genetically confirmed patients with SMA receiving optimal supportive care and without any disease-modifying treatment were stratified into Types 1 (n = 28) and 2/3 SMA (n = 63). Patients with Type 1 SMA weighed significantly less (median = -7.5%) compared with reference values and patients with Types 2/3 SMA were significantly shorter (mean = -3.0%) compared with reference values. The median weight was considerably below the 50th percentile in both groups of patients, even if they received a high standard of care and proactive feeding support. Discussion More research is needed to understand which factors influence growth longitudinally, and how to accurately capture growth in patients with SMA. Further research should investigate the best time to provide feeding support to avoid underweight, especially in patients with Type 1, and how to avoid the risk of overfeeding, especially in patients with Types 2/3 SMA.